Comparison of the efficacy and safety of a picosecond alexandrite laser and a Q-switched alexandrite laser for the treatment of freckles in Chinese patients
To the Editor: Recently, the picosecond pulsed alexandrite laser (PSAL) has shown promising results in treating freckles. 1 However, direct comparison between the PSAL and Q-switched alexandrite laser (QSAL) is still lacking. This study aimed to investigate the efficacy and safety of the PSAL compared with those of the QSAL for treating freckles in a split-face manner.
A total of 20 Chinese women presenting with facial freckles were enrolled in this study. The lasers used in this study were the PicoSure PSAL (Cynosure, Westford, MA) and the Accolade QSAL (Cynosure, Westford, MA). The right and left sides of the face were randomly assigned to either the control (QSAL-treated) group or experimental (PSALtreated) group. Standardized photographs were taken before the treatment and at the 2-month post-treatment follow-up. Blinded evaluation was conducted by 3 independent dermatologists. The lesion clearance rate was defined as the number of lesions before treatment minus the number of lesions after treatment divided by the number of lesions before treatment times 100%. Subject satisfaction and pain level were also evaluated by using a Likert scale and a visual analog scale pain score, respectively. Four patients were examined by reflectance confocal microscopy (RCM) to observe the microstructural changes in the tissue of the lesion.
The average clearance rates of the experimental group and control group were 76.9% plus or minus 12% and 75.6% plus or minus 13%, respectively. There were no significant differences in lesion clearance rate (t ¼ 0.841; P ¼ .411), visual analog scale score (t \ 0.001; P ¼ 1.000), or patient satisfaction (t ¼ e0.568; P ¼ .577) (Fig 1) . The levels and durations of adverse reactions such as erythema, edema, crusting, oozing, hyperpigmentation, hypopigmentation, blisters, scars, and infection were not statistically significantly different between the experimental and control groups (Z ¼ e0.
Most of the subjects had mild-to-moderate erythema and edema after treatment, which subsided after 1 to 2 days and crusted off after 4 to 5 days. In this study, the average fluences used in the experimental and control groups were 4.4 J/cm 2 and 6.92 J/cm 2 , respectively. It was observed that the PSAL utilized a lower fluence to achieve acceptable lesion clearance.
The RCM images indicated that many highrefractive melanin particles were in the stratum spinosum in the baseline images. Two weeks after the treatment, the number of melanin particles had decreased in both groups. The RCM images revealed that subjects in the control group treated with the QSAL had spines of highly refractive dendritic cells-a finding similar to that of Yamashita et al. The authors speculated that the dendritic cells might be melanocytes and that heat damage led to changes in melanin traits that in turn increased the refractive index, whereas laser stimulation led to the migration of more melanocytes from hair follicles to the normal-appearing epidermis; damaged melanin particles cannot be transported to keratinocytes and thus remain in melanocytes. However, this phenomenon was not observed in the experimental group treated with the PSAL. We speculated that this may due to the relatively lesser photothermal damage by the PSAL (Fig 2) .
Our results suggested that the efficacy and safety of using a PSAL for treating freckles in Chinese patients are comparable to those of using a QSAL. To the Editor: The role of neurocutaneous pathways in the pathogenesis of psoriasis has been suggested in cases of dermatomal improvement in psoriatic plaques following central or peripheral nerve damage [1] [2] [3] ; however, few studies have assessed the effect of nerve-targeting treatments, 4 ,5 especially in plaque psoriasis. This study investigated the effect of onabotulinumtoxinA injections on psoriasis severity, epidermal nerve fiber (ENF) density, and expression of the neuropeptides substance P (SP) and calcitonin geneerelated peptide (CGRP).
In this single-center pilot study, 8 subjects (Fig 1,  A and B) with plaque psoriasis received a 1-time injection of onabotulinumtoxinA (Botox, Allergan, Inc, Irvine, CA) throughout a single target plaque (average units, 53; range, 25-98) and were followed for 10 weeks after the injection with assessment of their Psoriasis Area and Severity Index (PASI) score and Physician's Global Assessment (PGA) score and clinical photography. Punch biopsy specimens (diameter, 3 mm) obtained from lesional and perilesional skin 2 weeks before and 8 weeks after Reflectance confocal microscopy (RCM) images for 1 patient: image from an area of the patient's face randomized to the control (Q-switched alexandrite laseretreated) group before treatment (A) and at 2 weeks after treatment with a Q-switched alexandrite laser (B) and image from an area of the patient's face randomized to the experimental ( picosecond pulsed alexandrite laseretreated) group before treatment (C) and at 2 weeks after treatment (D). A and C, Arrows indicate the many high-refractive melanin particles the stratum spinosum. B, Arrow indicates the decrease in the number of melanin particles and spines of highly refractive dendritic cells in the stratum spinosum after treatment. D, Arrow indicates the decrease in the number of melanin particles in the stratum spinosum after treatment.
